About

About IONTAS

History

IONTAS was founded by John McCafferty the co-discoverer of antibody phage display for which Professor Greg Winter was awarded the Nobel prize in Chemistry in 2018. The company began operations in October 2012 by offering antibody discovery services via phage display. From the outset the company re-invested profits to increase the efficiency of antibody drug discovery process and to develop other display technologies. This resulted in the development of Mammalian Display, a novel platform for identifying high affinity, developable lead antibody candidates.

FairJourney Biologics and IONTAS combined capabilities in 2020 as a fee for service antibody discovery company. The combined operations allow a complete offering around antibody discovery. Uses fully validated naïve libraries with parallel immune approaches and the unrivalled mammalian display technology to optimise antibody discovery research. The team of more than 100 scientists, anchored in a high-profile network of advisors, has successfully completed more than 500 projects, with over 100 biotechnology and pharmaceutical companies.

View our technologies

One brand, three companies.

Our distinct and leading international brands joined forces to enable our current and future partners access to premium antibody discovery solutions, including the ability to leverage highly sought-after scientific know-how and expertise across our unified organization.

This combination creates a leading global antibody discovery CRO within our industry, offering unparalleled antibody services and technology platforms to global biopharmas , biotechs, universities, virtual companies and other innovative partnerships.

FairJourney Biologics

FairJourney Biologics is a leading biologics CRO, providing integrated services across antibody discovery, engineering and production to global biopharma. The Company’s significant expertise in phage display technology, combined with a diverse approach to generating both immune and naïve antibody libraries have contributed to a market leading 99%+ project success rate.

Visit website

IONTAS

IONTAS offers services for antibody discovery using Phage Display Technology and Mammalian Display. The innovative Mammalian Display platform enables full-length antibodies to be expressed in the context of a mammalian cell, thereby allowing selection based on function, stability, expression and developability.

Visit website

Flow Eighteen38

Flow Eighteen38 offers antibody production, from 96-well plates to deliver micrograms up to large scale, to deliver grams. Flow Eighteen38's services also comprise technologies for further functional and biophysical characterization including mass spectrometry, SPR, DLS, SLS, cIEF, CE-SDS, and chromatography methods. The services include antigen production, for use as immunogens and to generate new antibodies and reagents for research.

Visit website

Notable numbers
about our network

View our technologies

Our Story

Our organization was founded in 2012, with the goal of becoming the leader in antibody discovery by solving our clients needs. Since then, we have grown from strength to strength serving over 100 customers and completing over 500 projects worldwide. View some of our milestones by scrolling across.

  • 2012 Incorporation
    FairJourney Biologics and IONTAS incorporated
  • 2012
    1st Project and 1st Lab
  • 2013
    1st FTE contract Profitable
  • 2014
    1st Internal project
  • 05/2014
    VHH llama library
  • 06/2015
    1st Big pharma contract
  • 08/2015
    Human Library
  • 07/2016
    3200m2 New facilities
  • 08/2017
    Mammalian Display Patent
  • 11/2017
    Triple Vector patent
  • 2018
    1st Co-developed
    antibody licensed
  • 2019
    1st Licence on
    Mammalian Display
  • 05/2020
    IONTAS acquisition

Flow Eighteen38 launch

“We see Flow Eighteen38 as a significant milestone in combining knowledge across our organization into a new business unit. We look forward to expanding on our innovation in antibody discovery into the protein purification and characterization space, to offer faster and quality solutions for our current and future partners.”

This site uses cookies to provide you with a great user experience. By using our website, you accept our use of cookies.